THE MANAGEMENT OF WOMEN WITH THROMBOPHILIA IN PREPARATION FOR IN VITRO FERTILIZATION

封面


如何引用文章

全文:

详细

The aim was to study changes in the hemostatic system in women with hereditary and acquired thrombophilia in IVF cycle, the possibility of their drugs correction, as well as the effect of this therapy on the outcome of IVF. We examined 119 women with congenital or acquired thrombophilia during preparation or during IVF cycle. In the presence of abnormalities in laboratory data, combination of weight adjusted dose of the low molecular weight heparin, low dose aspirin and folic acid administered to the severity of coagulation disorders and homocystein level. In the group of patients with a history 3 or more IVF failures APS was diagnosed in 36.6 % of women. In this group the frequency of mutations in genes: PAI-1, PLAT, fibrinogen was significantly higher than in control group (83.3 % and 58.33 %, 40 % and 19.44 %, 50 % and 25 % respectively, p < 0.05), as well as mutations in genes PAI-1 and PLAT combination rate (31.03 % and 13.89 % respectively, p < 0,05) and the frequency of combinations of 3 or more mutations (65.51 % and 19.44 %, p < 0.001). In the group of women with thrombophilia (n = 97) treated with this therapy 52.57 % IVF cycles was successful. At 36.08 % pregnancies ended with childbirth. In the subgroup of women with 3 or more IVF failures (n = 26) the pregnancy rate was 38.46 %.

作者简介

Marina Mirashvili

FSBI “D. O. Ott Research Institute of Obstetrics and Gynecology” NWB RAMS

Email: mmirashvili@mail.ru
resident

Marina Zaynulina

FSBI “D. O. Ott Research Institute of Obstetrics and Gynecology” NWB RAMS

Email: iagmail@ott.ru
prof., M.D., Deputy director for clinical and scientific work

Igor Kogan

FSBI “D. O. Ott Research Institute of Obstetrics and Gynecology” NWB RAMS

Email: ikogan@mail.ru
M.D., docent, Academic Secretary

Aleksandr Gzgzyan

FSBI “D. O. Ott Research Institute of Obstetrics and Gynecology” NWB RAMS

Email: agzgzyan@hotmail.com
M.D, Head of the Department of assisted reproductive technology

Roza Rzayeva

FSBI “D. O. Ott Research Institute of Obstetrics and Gynecology” NWB RAMS

Email: r.rzaeva@yandex.ru
resident

参考

  1. Шмелева В. М. Роль гипергомоцистеинемии в формировании протромботических нарушений системы гемостаза: автореф... д-ра мед. наук. — СПб., 2010 . — 30 с.
  2. Antigenic profile, prevalence, and clinical significance of antiphospholipid antibodies in women referred for in vitro fertilization / Sanmarco M. [et al.] // Ann. N. Y. Acad. Sci. — 2007. — Vol. 1108. — P. 457–465.
  3. Antinuclear antibody reduces the pregnancy rate in the first IVF-ET treatment cycle but not the cumulative pregnancy rate without specific medication / Kikuchi K. [et al.] // Am. J. Reprod. Immunol. — 2003. — Vol. 50, N 4. — 363–367.
  4. Antiphospholipid antibodies and pregnancy rates and outcome in in vitro fertilization patients / Denis A. L. [et al.] // Fertil. Steril. — 1997. — Vol. 67. — P. 1084–1090.
  5. Antiphospholipid antibodies in women having in vitro fertilization / Birdsall M. A. [et al.] // Hum. Reprod. — 1996. — Vol. 11. — P. 1185–1189.
  6. Aune B., Oian P., Osterud B. Enhanced sensitivity of the extrinsic coagulation system during ovarian stimulation for in-vitro fertilization // Hum. Reprod. — 1993. — Vol. 8. — P. 1349–1352.
  7. Chan W. S., Dixon M. E. The «ART» of thromboembolism: a review of assisted reproductive technology and thromboembolic complications // Thromb. Res. —2008. — Vol. 121, N 6. — P. 713–726.
  8. Combined jugular and subclavian vein thrombosis following assisted reproductive technology: new observation / Salomon O. [et al.] // Fertil Steril 2009. — Vol. 92, N 2. — P.620–625.
  9. Detection of a procoagulable state during controlled ovarian hyperstimulation for in vitro fertilization with global assays of haemostasis / Westerlund E. [et al.] // Thromb. Res. — 2011. —Dec 7. [Epub ahead of print].
  10. Diagnostic evaluation of women experiencing repeated in vitro fertilization failure / Vaquero E. [et al.] // Eur. J. Obstet. Gynecol. Reprod. Biol. — 2006. — Vol. 125, N 1. — P.79–84.
  11. Does ovarian stimulation for in-vitro fertilization induce a hypercoagulable state? / Aune B. [et al.] // Hum. Reprod. — 1991. — Vol. 6. — P. 925–927.
  12. Embryo implantation after assisted reproductive procedures and maternal thrombophilia / Martinelli I. [et al.] // Haematologica. — 2003. — Vol. 88, N 7. — P. 789–793.
  13. Fiedler K., Würfel W. Effectivity of heparin in assisted reproduction // Eur. J. Med. Res. — 2004. — Vol. 9, N 4. — P. 207–214.
  14. Heby O. DNA methylation and polyamines in embryonic development and cancer // Int. J. Dev. Biol. — 1995. — Vol. 39. — P. 753–757.
  15. Hemostasis parameters during ovarian stimulation for in vitro fertilization: results of a prospective study / Biron C. [et al.] // Fertil. Steril. — 1997. — Vol. 67. — P. 104–109.
  16. In vitro fertilization. Do short-term changes in estrogen levels produce increased fibrinolysis? / Magnani B. [et al.] // Am. J. Clin. Pathol. — 1999. — Vol. 112. — P.485–491.
  17. In vitro fertilization-induced alterations in coagulation and fibrinolysis as measured by thromboelastography / Harnett M. J. [et al.] // Anesth. Analg. — 2002. — Vol. 95, N 4. — P.1063–1066.
  18. Incidence of autoimmune antibodies in failed embryo transfer cycles / Birkenfeld A. [et al.] // Am. J. Reprod. Immunol. — 1994. — Vol. 31. — P. 65–68.
  19. Increased rates of thrombophilia in women with repeated IVF failure / Azem F. [et al.] // Hum. Reprod. — 2004. — Vol. 19. — P. 368–370.
  20. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial / Qublan H. // Hum. Fertil. — 2008. — Vol. 11, N 4. — P. 246–253.
  21. Lox C., Canez M., Prien S. The influence of hyperestrogenism during in vitro fertilization on the fibrinolytic mechanism // Int. J. Fertil. Womens Med. — 1998. — Vol. 43. — P. 34–39.
  22. Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial / Urman B. [et al.] // Hum. Reprod. — 2009. — Vol. 24, N 7. — P. 1640–1647.
  23. More on: the ‘ART’ behind the clot – solving the mystery / Bauersachs R. M.[et al.] // J. Thromb. Haemost. — 2007. — Vol. 5. — P. 438–439.
  24. Nelson S. M. Prophylaxis of VTE in women — during assisted reproductive techniques // Thromb. Res. — 2009. — Vol. 123. — P. 8–15.
  25. Prediction of changes in levels of haemostatic variables during natural menstrual cycle and ovarian hyperstimulation / Andersson O. [et al.] // Thromb. Haemost. — 1997. — Vol. 77. — P. 901–904.
  26. Sharif K. W., Ghunaim S. Management of 273 cases of recurrent implantation failure: results of a combined evidence-based protocol // Reprod Biomed Online. — 2010. — Vol. 21, N 3. — P. 373–380.
  27. The cumulative incidence of venous thromboembolism during pregnancy and puerperium: an 11 year Danish population based study of 63 300 pregnancies / Anderson B. S. [et al.] // Acta Obstet. Gynecol. Scand. — 1998. — Vol. 77. — P. 110–113.
  28. The European IVF-monitoring (EIM) Consortium, for the European Society of Human Reproduction and Embryology (ESHRE) / J. de Mouzon [et al.] // Hum. Reprod. — 2010. — Vol. 25, N 8. — P. 1851–1862. — (Assisted reproductive technology in Europe, 2006: results generated from European registers by ESHRE).
  29. The possible role of hyperhomocysteinemia on IVF outcome / Pacchiarotti A. [et al.] // J. Assist. Reprod. Genet. — 2007. — Vol. 24, N 10. — P. 459–462.
  30. Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis / Di Nisio M. [et al.] // Blood. — 2011. — Vol. 118, N 10. — P. 2670–2678.

版权所有 © Mirashvili M.I., Zaynulina M.S., Kogan I.Y., Gzgzyan A.M., Rzayeva R.N., 2012

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可

##common.cookie##